SEARCH

SEARCH BY CITATION

References

  • 1
    Siegel, R., D. Naishadham, and A. Jemal. 2013. Cancer statistics, 2012. CA Cancer J. Clin. 62:1029.
  • 2
    Boyle, P., and J. Ferlay. 2005. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16:481488.
  • 3
    Rachet, B., E. Mitry, A. Shah, N. Cooper, and M. P. Coleman. 2008. Survival from multiple myeloma in England and Wales up to 2001. Br. J. Cancer 99(Suppl. 1):S110S112.
  • 4
    Kumar, S. K., S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, et al. 2008. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:25162520.
  • 5
    Rajkumar, S. V., S. Jacobus, N. S. Callander, R. Fonseca, D. H. Vesole, M. E. Williams, et al. 2010. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11:2937.
  • 6
    Sonneveld, P., I. G. H. Schmidt-Wolf, B. van der Holt, L. El Jarari, U. Bertsch, H. Salwender, et al. 2012. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J. Clin. Oncol. 30:29462955.
  • 7
    Kumar, S. K., A. Dispenzieri, M. A. Gertz, M. Q. Lacy, J. A. Lust, S. R. Hayman, et al. 2012. Continued improvement in survival in multiple myeloma and the impact of novel agents. ASH Annu. Meet. Abs. 120:3972.
  • 8
    Anguiano, A., S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, et al. 2009. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J. Clin. Oncol. 27:41974203.
  • 9
    Mikhael, J. R., D. Dingli, V. Roy, C. B. Reeder, F. K. Buadi, S. R. Hayman, et al. 2013. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88:360376.
  • 10
    Avet-Loiseau, H., M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, et al. 2007. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myélome. Blood 109:34893495.
  • 11
    Stewart, A. K., and R. Fonseca. 2005. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J. Clin. Oncol. 23:63396344.
  • 12
    Munshi, N. C., K. C. Anderson, P. L. Bergsagel, J. Shaughnessy, A. Palumbo, B. Durie, et al. 2011. Consensus recommendations for risk stratification in multiple myeloma: report of the international myeloma workshop consensus panel 2. Blood 117:46964700.
  • 13
    Morgan, G. J., B. A. Walker, and F. E. Davies. 2012. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12:335348.
  • 14
    Kuehl, W. M., and P. L. Bergsagel. 2012. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 122:34563463.
  • 15
    Palumbo, A., S. Bringhen, H. Ludwig, M. A. Dimopoulos, J. Bladé, M. V. Mateos, et al. 2011. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European myeloma network (EMN). Blood 118:45194529.
  • 16
    Greipp, P. R., J. San Miguel, B. G. M. Durie, J. J. Crowley, B. Barlogie, J. Bladé, et al. 2005. International staging system for multiple myeloma. J. Clin. Oncol. 23:34123420.
  • 17
    Kleber, M., G. Ihorst, B. Gross, B. Koch, H. Reinhardt, R. Wäsch, et al. 2013. Validation of the freiburg comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin. Lymphoma Myeloma leuk. 13:541551.
  • 18
    Chakraborty, S., R. J. Hauke, N. Bonthu, and S. R. Tarantolo. 2012. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma – a SEER based study. Anticancer Res. 32:45074515.
  • 19
    Tsuchiya, J., H. Murakami, T. Kanoh, M. Kosaka, T. Sezaki, C. Mikuni, et al. 1994. Ten-year survival and prognostic factors in multiple myeloma. Br. J. Haematol. 87:832834.
  • 20
    Finnish Leukaemia Group. 1999. Long-term survival in multiple myeloma: a Finnish leukaemia group study. Br. J. Haematol. 105:942947.
  • 21
    Merchionne, F., P. Procaccio, and F. Dammacco. 2008. Long-term survival in multiple myeloma: a single-center experience. Clin. Exp. Med. 8:133139.
  • 22
    Bryant, C., H. Suen, R. Brown, S. Yang, J. Favaloro, E. Aklilu, et al. 2013. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 3:e148.
  • 23
    Durie, B. G. M., J.-L. Harousseau, J. S. Miguel, J. Bladé, B. Barlogie, K. Anderson, et al. 2006. International uniform response criteria for multiple myeloma. Leukemia 20:14671473.
  • 24
    1998. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma trialists' collaborative group. J. Clin. Oncol. 16:38323842.
  • 25
    Egan, J. B., C.-X. Shi, W. Tembe, A. Christoforides, A. Kurdoglu, S. Sinari, et al. 2012. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 12010601066.
  • 26
    Fonseca, R., and J. Monge. 2013. Myeloma: classification and risk assessment. Semin. Oncol. 40:554566.
  • 27
    Landgren, O., and G. J. Morgan. 2014. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin. Cancer Res. 20:804813.
  • 28
    Avet-Loiseau, H., M. Attal, L. Campion, D. Caillot, C. Hulin, G. Marit, et al. 2012. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J. Clin. Oncol. 30:19491952.
  • 29
    Rajkumar, S. V., G. Gahrton, and P. L. Bergsagel. 2011. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118:32053211.
  • 30
    Mikhael, J. R., D. Dingli, V. Roy, C. B. Reeder, F. K. Buadi, S. R. Hayman, et al. 2013. Pp. 360376 in Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (MSMART) consensus guidelines. Mayo Clin. Proc. 88:360376.
  • 31
    Zamagni, E., S. Bringhen, L. Pantani, A. Pezzi, B. A. Zannetti, P. Tacchetti, et al. 2013. Superior outcomes with bortezomib or thalidomide incorporated into autologous stem cell transplantation (ASCT) versus novel agent-based treatments for Elderly patients with newly diagnosed multiple myeloma (MM): a case-match comparison. Blood 122:3344.
  • 32
    Chubak, J., L. Tuzzio, C. Hsu, C. M. Alfano, B. A. Rabin, M. C. Hornbrook, et al. 2012. Providing care for cancer survivors in integrated health care delivery systems: practices, challenges, and research opportunities. J. Oncol. Pract. 8:184189.
  • 33
    Campbell, M. K., I. Tessaro, M. Gellin, C. G. Valle, S. Golden, L. Kaye, et al. 2011. Adult cancer survivorship care: experiences from the LIVESTRONG centers of excellence network. J. Cancer Surviv. 5:271282.
  • 34
    Othus, M., B. Barlogie, M. L. Leblanc, and J. J. Crowley. 2012. Cure models as a useful statistical tool for analyzing survival. Clin. Cancer Res. 18:37313736.
  • 35
    Félix, J., F. Aragão, J. M. Almeida, F. J. Calado, D. Ferreira, A. B. S. Parreira, et al. 2013. Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer 13:122.